GlassScriptPhysician profile
Douglas R King
NPI 1184643611
$2,055.39
in general payments reported to CMS, 2019-2025
18 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,729 · 2020: $120 · 2022: $21.03 · 2023: $20.81 · 2024: $18.05 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $185.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuvasive, INC. | $1,560.57 | 2019 | |
| Conmed Corporation | $146.31 | 2025 | Airseal |
| Amgen INC. | $34.55 | 2020 | |
| Merck Sharp & Dohme LLC | $34.51 | 2019-2024 | Bridion |
| Dendreon Pharmaceuticals LLC | $28.14 | 2020 | |
| Seagen INC. | $26.18 | 2019 | |
| Encision INC | $21.03 | 2022 | |
| Davol INC. | $20.81 | 2023 | Bard 3dmax Mesh |
| Mylan Institutional INC. | $20.36 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $20.29 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.89 | 2019 | |
| Rigel Pharmaceuticals, INC. | $18.90 | 2019 | |
| Coherus Oncology, INC. | $18.78 | 2020 | |
| Incyte Corporation | $18.45 | 2020 | |
| Ferring Pharmaceuticals INC. | $18.19 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17.73 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $16.25 | 2019 | |
| Ethicon US, LLC | $14.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.